Evidence map›Paper›PMID 38834986›Full record

ArticleCancer cell international2024

Syntaxin6 contributes to hepatocellular carcinoma tumorigenesis via enhancing STAT3 phosphorylation.

Li Huang, Xiaoting Zhong, An Li, Fuping Tu, Miao He, Xueming Xu, Xiaohui Liu, Xiaoli Zeng, Jun Chi, Tian Tian and 3 more

Abstract read
In one paragraph

Article in Cancer cell international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Li Huang *Department of oncology, First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
Xiaoting Zhong *Department of oncology, First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
An LiDepartment of oncology, First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
Fuping TuDepartment of oncology, First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
Miao HeDepartment of oncology, First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
Xueming XuDepartment of oncology, First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
Xiaohui LiuDepartment of oncology, First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
Xiaoli ZengDepartment of oncology, First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
Jun ChiDepartment of oncology, First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
Tian TianGannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, China.
Chunli WangDepartment of critical medicine, First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
Xiangcai WangDepartment of oncology, First Affiliated Hospital, Gannan Medical University, Ganzhou, China. wangxiangcai@csco.ac.cn.ORCID https://orcid.org/0000-0002-7162-0552
Jianming YeDepartment of oncology, First Affiliated Hospital, Gannan Medical University, Ganzhou, China. yejianming@gmu.edu.cn.ORCID https://orcid.org/0000-0003-3215-7726

Funding

Henan Charity Federation Hepatobiliary Fund GDXZ2024001, T. T.Science and Technology Program of Jiangxi Provincial Health Committee No. 202310830Science and Technology Research Project of the Education Department of Jiangxi Province No. GJJ211512
6 · The paper itself

Abstract

backgroundSyntaxin6 (STX6) is a SNARE (Soluble N-ethylmaleimide-sensitive factor attachment protein receptors) protein complex located in the trans-Golgi network and endosomes, which is closely associated with a variety of intracellular membrane transport events. STX6 has been shown to be overexpressed in a variety of human malignant tumors such as esophageal, colorectal, and renal cell carcinomas, and participates in tumorigenesis and development.

methodsBased on clinical public database and clinical liver samples analysis, the expression of STX6 in hepatocellular carcinoma (HCC) tissues was investigated. The effects of STX6 on proliferation, migration and invasion of HCC cell in vitro and in vivo were evaluated through gain- and loss-of-function studies. We further performed RNA-seq analysis and protein interactome analysis, to further decifer the detailed mechanisms of STX6 in the regulation of the JAK-STAT pathway in HCC.

resultsSTX6 expression was upregulated in HCC tissues and its expression was highly correlated with the high histological grade of the tumor. STX6 promoted HCC cell proliferation, migration and invasion both in vitro and in vivo. Mechanistically, STX6 mediated tumor progression depending on promoting the activation of JAK-STAT signaling pathway. Receptor for activated protein kinase C (RACK1) as an essential adaptor protein mediating STX6 regulation of JAK-STAT pathway. Specifically, STX6 interacted with RACK1 and then recruited signal transducer and activator of transcription 3 (STAT3) to form a protein-binding complex and activates STAT3 transcriptional activity.

conclusionsThis study provided a novel concept that STX6 exerted oncogenic effects by activating the STAT3 signaling pathway, and STX6 might be a promising therapeutic target for HCC.

Indexed as

HCCJAK-STATSTAT3STX6Tumorigenesis

Identifiers

PMID38834986
PMCPMC11149193

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.